Latest News
IRLAB Therapeutics receives US patent allowance for Parkinson's drug candidate IRL1117
27 October 2026 - IRLAB Therapeutics AB (STO:IRLAB-A), a Swedish developer of new treatments for Parkinson's disease, said on Tuesday that it has received a Notice of Allowance from the US Patent and Trademark Office for its drug candidate IRL11...
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult
27 October 2026 - Thor Medical ASA (OSE:TRMED), a supplier of alpha-emitters for precision cancer treatment, said on Tuesday that it has signed a three-year supply agreement with Medicines Discovery Catapult (MDC) to support the development of radiop...
Enhertu wins EU approval for HER2-positive early breast cancer treatment
27 October 2026 - Biopharmaceutical company AstraZeneca plc (LSE/STO/NYSE: AZN) and its Japanese pharmaceutical partner Daiichi Sankyo (TYO: 4568) said on Tuesday that the European Commission has approved Enhertu (trastuzumab deruxtecan) as a monothe...
Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418
27 October 2026 - Clinical-stage biotechnology company Riboscience LLC announced on Monday the presentation of initial overall survival (OS) and immune activation data from the Phase 1a/b clinical trial of RBS2418, its oral inhibitor of ENPP1, at the...
Lilly to pay Q4 dividend of USD1.73
27 October 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Monday that its board of directors has declared a dividend of USD1.73 per share of common stock for the fourth quarter of 2026.This amount is unchanged from the...